var data={"title":"VIPoma: Clinical manifestations, diagnosis, and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">VIPoma: Clinical manifestations, diagnosis, and management</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Emily Bergsland, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Kenneth K Tanabe, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 31, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VIPomas are rare functioning neuroendocrine tumors that secrete vasoactive intestinal polypeptide (VIP). This topic will review the clinical manifestations, diagnosis, and management of VIPomas. An overview of the clinical manifestations, diagnosis, and management of pancreatic neuroendocrine tumors and other functioning pancreatic neuroendocrine tumors are discussed in detail, separately. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a> and <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;</a> and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">&quot;Insulinoma&quot;</a> and <a href=\"topic.htm?path=somatostatinoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Somatostatinoma: Clinical manifestations, diagnosis, and management&quot;</a> and <a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">&quot;Glucagonoma and the glucagonoma syndrome&quot;</a> and <a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">&quot;Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1081550639\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VIPomas are detected in 1 in 10 million people per year [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. The majority of VIPomas arise within the pancreas, and are classified as functioning pancreatic neuroendocrine (islet cell) tumors. In adults, VIPomas are intrapancreatic in over 95 percent of cases. However, other VIP-secreting tumors have been reported, including lung cancer, colorectal cancer, ganglioneuroblastoma, pheochromocytoma, hepatoma, and adrenal tumors. In children, VIPomas can occur in sympathetic ganglia and the adrenal glands [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145093\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Classification and nomenclature'</a>.)</p><p>VIPomas are usually diagnosed between 30 and 50 years of age in adults and between two and four years of age in children. Symptomatic pancreatic VIPomas are usually solitary, more than 3 cm in diameter, and occur in the tail of the pancreas in 75 percent of patients. Approximately 60 to 80 percent of VIPomas have metastasized by the time of diagnosis [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/2,3\" class=\"abstract_t\">2,3</a>]. VIPomas usually occur as isolated tumors, but in 5 percent of patients they are part of the multiple endocrine neoplasia syndrome type 1 (MEN1) and occur in association with parathyroid and pituitary tumors, gastrinoma, and other tumors [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The VIPoma syndrome is caused by excessive, unregulated secretion of vasoactive intestinal polypeptide (VIP) by the tumor. However, other substances, such as prostaglandin E2, may occasionally be secreted by the tumors [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"abstract_t\">5</a>]. VIP is a 28 amino acid polypeptide that binds to high affinity receptors on intestinal epithelial cells, leading to activation of cellular adenylate cyclase and cAMP production. This results in net fluid and electrolyte secretion into the lumen, resulting in secretory diarrhea and hypokalemia [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Other biologic actions of VIP including vasodilation, inhibition of gastric acid secretion, bone resorption, and enhanced glycogenolysis are responsible for flushing as well as laboratory findings of hypochlorhydria, hypercalcemia, and hyperglycemia in patients with VIPomas (<a href=\"image.htm?imageKey=GAST%2F52546\" class=\"graphic graphic_table graphicRef52546 \">table 1</a>). (See <a href=\"topic.htm?path=vasoactive-intestinal-polypeptide\" class=\"medical medical_review\">&quot;Vasoactive intestinal polypeptide&quot;</a> and <a href=\"#H3\" class=\"local\">'Clinical features'</a> below and <a href=\"topic.htm?path=physiology-of-gastric-acid-secretion\" class=\"medical medical_review\">&quot;Physiology of gastric acid secretion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H1081550670\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of patients with VIPoma have VIPoma syndrome, which is also called the pancreatic cholera syndrome, Verner-Morrison syndrome, and the watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria (WDHA) syndrome. VIPoma syndrome is characterized by watery diarrhea that persists with fasting. Stools are tea-colored and odorless with stool volumes exceeding 700 <span class=\"nowrap\">mL/day</span>. In 70 percent of patients, stool volume can exceed 3000 <span class=\"nowrap\">mL/day</span> [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/7-9\" class=\"abstract_t\">7-9</a>]. Abdominal pain is mild or absent. Associated symptoms include flushing episodes in 20 percent of patients and symptoms related to hypokalemia and dehydration, such as lethargy, nausea, vomiting, muscle weakness, and muscle cramps (<a href=\"image.htm?imageKey=GAST%2F52546\" class=\"graphic graphic_table graphicRef52546 \">table 1</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-hypokalemia-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of hypokalemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1081550664\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with VIPoma have secretory diarrhea with a low osmotic gap (&lt;50 <span class=\"nowrap\">mOsm/kg)</span> (<a href=\"topic.htm?path=calculator-stool-osmolal-gap\" class=\"calc calc_professional\">calculator 1</a>) [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"abstract_t\">10</a>]. Hypochlorhydria occurs in 75 percent of patients and can result in iron and B12 deficiency. Other findings may include hyperglycemia and hypercalcemia (<a href=\"image.htm?imageKey=GAST%2F52546\" class=\"graphic graphic_table graphicRef52546 \">table 1</a>). Hypercalcemia may be due to coexistent hyperparathyroidism as part of the MEN1 syndrome or to hyperalbuminemia caused by dehydration. In patients with dehydration, the serum total calcium concentration is increased, but the serum ionized (or free) calcium concentration is normal. (See <a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia#H2\" class=\"medical medical_review\">&quot;Diagnostic approach to hypercalcemia&quot;, section on 'Confirm hypercalcemia'</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings#H18\" class=\"medical medical_review\">&quot;Approach to the adult with chronic diarrhea in resource-rich settings&quot;, section on 'Specific testing'</a>.)</p><p class=\"headingAnchor\" id=\"H390935\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of a VIPoma is suspected in patients with unexplained high-volume secretory diarrhea (&gt;700 <span class=\"nowrap\">mL/day)</span>. The diagnosis is established by a serum vasoactive intestinal polypeptide (VIP) concentration &gt;75 <span class=\"nowrap\">pg/mL</span>. However, a single elevated VIP level should be confirmed by repeat testing. </p><p>Evaluation of the patient with secretory diarrhea to exclude other causes is discussed in detail, separately. (See <a href=\"#H1081550940\" class=\"local\">'Differential diagnosis'</a> below and <a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings#H19\" class=\"medical medical_review\">&quot;Approach to the adult with chronic diarrhea in resource-rich settings&quot;, section on 'Secretory diarrhea'</a>.)</p><p class=\"headingAnchor\" id=\"H1081550940\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other disorders that can cause secretory diarrhea include surreptitious abuse of saline cathartics, enteritis caused by enterotoxigenic <em>Escherichia coli</em> or <em>Vibrio cholera</em>, microscopic colitis, bile salt malabsorption due to ileal resection, and the carcinoid syndrome (<a href=\"image.htm?imageKey=GAST%2F65916\" class=\"graphic graphic_table graphicRef65916 \">table 2</a>). (See <a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings#H19\" class=\"medical medical_review\">&quot;Approach to the adult with chronic diarrhea in resource-rich settings&quot;, section on 'Secretory diarrhea'</a>.)</p><p class=\"headingAnchor\" id=\"H391020\"><span class=\"h1\">TUMOR LOCALIZATION</span></p><p class=\"headingAnchor\" id=\"H1081551097\"><span class=\"h2\">Approach to imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After diagnosis, imaging studies are required to accurately localize the tumor. Cross-sectional imaging with multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen can localize the tumor and stage the extent of disease. We begin with helical (spiral) multiphasic contrast-enhanced CT for evaluation of patients with a VIPoma. We perform MRI when CT shows indeterminate lesions that need further characterization. If cross-sectional imaging is inconclusive, endoscopic ultrasound (EUS), somatostatin receptor scintigraphy, or Gallium-68-DOTA-D-Phe1-Tyr3-Octreotate (<a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> <span class=\"nowrap\">PET/CT)</span> should be performed to identify the tumor. Because of its greater sensitivity, 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> may be preferable to conventional somatostatin receptor scintigraphy, if available [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In addition, we perform somatostatin receptor scintigraphy or 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> in the evaluation of a patient with VIPoma if the finding of extra-abdominal metastases would change treatment. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145128\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Indium-111 pentetreotide (OctreoScan)'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Computed tomography</strong> &ndash; CT scan is noninvasive and readily available. Intravenous contrast enhances the detection of smaller lesions, especially when images are obtained during the arterial phase. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared with the surrounding normal liver parenchyma. CT scans are highly accurate for detecting primary pancreatic NETs, and, using multiphase imaging techniques, sensitivity is &gt;80 percent [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/13-15\" class=\"abstract_t\">13-15</a>]. Since most pancreatic VIPomas are more than 3 cm in size at presentation, a pancreatic mass can usually be identified by CT in the majority of cases [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>]. The sensitivity of contrast-enhanced CT for these tumors approaches 100 percent [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/17,18\" class=\"abstract_t\">17,18</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145107\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Computed tomography'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Magnetic resonance imaging</strong> &ndash; On MRI, pancreatic NETs are typically characterized by low signal intensity on T1-weighted images and high signal intensity on T2-weighted images (<a href=\"image.htm?imageKey=ONC%2F59487\" class=\"graphic graphic_diagnosticimage graphicRef59487 \">image 1</a> and <a href=\"image.htm?imageKey=ONC%2F72303\" class=\"graphic graphic_diagnosticimage graphicRef72303 \">image 2</a>). MRI may have a higher sensitivity for liver metastases as compared with CT [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145114\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Magnetic resonance imaging'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Somatostatin receptor scintigraphy</strong> &ndash; Somatostatin receptor scintigraphy (OctreoScan) using radiolabeled form of the somatostatin analog <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (Indium-111 [111-In]) pentetreotide has the advantage of instantaneous whole body scanning, which also allows detection of metastases outside of the abdominal region [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"abstract_t\">20</a>]. While somatostatin-receptor scintigraphy is recommended in guidelines from the European Neuroendocrine Tumor Society, the British Society of Gastroenterology, and the European Society for Medical Oncology (ESMO), the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=2610\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN)</a> suggests its use &quot;if appropriate&quot; [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/21-23\" class=\"abstract_t\">21-23</a>]. However, other experts have suggested that somatostatin-receptor scintigraphy be used as an adjunct for tumor staging if the finding would change patient management [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145128\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Indium-111 pentetreotide (OctreoScan)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Endoscopic ultrasound</strong> &ndash; EUS can detect pancreatic tumors as small as 2 to 3 mm, provide accurate information on the local extent of disease, and allow for transmucosal needle biopsy of pancreatic lesions. However, EUS is rarely used in the evaluation of VIPomas as these tumors are diagnosed by hormonal assays and VIPomas are usually detectable on <span class=\"nowrap\">CT/MRI</span> at diagnosis. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Functional PET imaging techniques</strong> &ndash; Several positron emission tomography (PET) tracers for functional imaging have emerged (18-F-dihydroxy-phenyl-alanine [18F-DOPA], 11-C-5-hydroxytryptophan [11-C-5-HTP]), and 68-Ga-DOTA-D-Phe<sup>1</sup>-Tyr<sup>3</sup>-Octreotide (68-Ga-DOTATOC). A kit for preparation of 68-Ga DOTATATE injection as a radioactive diagnostic agent for PET imaging was approved by the United States Food and Drug Administration in June 2016 for adult and pediatric patients with somatostatin receptor positive neuroendocrine tumors (NETs) [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"abstract_t\">24</a>]. These novel PET modalities offer higher spatial resolution than conventional somatostatin receptor scintigraphy (SRS) and are associated with improved sensitivity for detection of small lesions. (See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring#H5\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;, section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two staging systems are available for pancreatic NETs, the tumor, node, metastasis (TNM) classification from the joint American Joint Committee on <span class=\"nowrap\">Cancer/Union</span> for International Cancer Control, and another proposed by the European Neuroendocrine Tumor Society (<a href=\"image.htm?imageKey=ONC%2F86409\" class=\"graphic graphic_table graphicRef86409 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"abstract_t\">25</a>]. Both staging systems are highly prognostic for both relapse-free and overall survival [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/26-28\" class=\"abstract_t\">26-28</a>]. The newest release of the TNM staging classification (8<sup>th</sup> edition, 2017), has a staging systems for neuroendocrine tumors of the pancreas (<a href=\"image.htm?imageKey=ONC%2F111355\" class=\"graphic graphic_table graphicRef111355 \">table 4</a>) that is separate from that used for exocrine pancreatic tumors [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H26599949\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Staging system'</a>.)</p><p class=\"headingAnchor\" id=\"H1664653297\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H1081550698\"><span class=\"h2\">Symptomatic treatment</span></p><p class=\"headingAnchor\" id=\"H1081550705\"><span class=\"h3\">Repletion of fluid and electrolytes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of a patient with a VIPoma begins with replacement of fluid losses and correction of electrolyte abnormalities. Many patients require more than 5 L of fluid and 350 mEq of potassium daily. (See <a href=\"topic.htm?path=maintenance-and-replacement-fluid-therapy-in-adults#H8\" class=\"medical medical_review\">&quot;Maintenance and replacement fluid therapy in adults&quot;, section on 'Replacement fluid therapy'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-hypokalemia-in-adults#H3820122\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of hypokalemia in adults&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Somatostatin analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatin and its analogs (eg, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a>, <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a>) inhibit the secretion of vasoactive intestinal polypeptide (VIP) and are the treatment of choice to control diarrhea in patients with VIPoma [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/30-32\" class=\"abstract_t\">30-32</a>]. Although somatostatin analogs are highly effective at controlling the symptoms of hormone hypersecretion, objective evidence of antitumor activity has not been clearly demonstrated. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90693975\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Somatostatin analogs'</a>.)</p><p>Symptomatic patients may be initiated on short-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (50 to 100 micrograms subcutaneously every eight hours) with rapid transition to a long-acting formulation and subsequent titration of dose to optimize symptom control [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/22,33\" class=\"abstract_t\">22,33</a>]. Sandostatin LAR, a depot preparation, is typically initiated at a dose of 20 mg IM monthly with gradual dose escalation as needed for optimal symptom control [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"abstract_t\">34</a>]. Patients may use additional short-acting octreotide for breakthrough symptoms while doses are being titrated; therapeutic levels of octreotide are not reached until 10 to 14 days after the initiation of the LAR injection. <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">Lanreotide</a>, another long-acting somatostatin analog, can be self-administered once monthly using a deep subcutaneous injection and appears to have similar efficacy to octreotide [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/35-37\" class=\"abstract_t\">35-37</a>].</p><p>Somatostatin analogs are usually well tolerated, but there are some side effects [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/38,39\" class=\"abstract_t\">38,39</a>]. About one-third of patients have nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first several weeks of therapy, after which the symptoms subside. Mild glucose intolerance rarely occurs, due to transient inhibition of insulin secretion. More importantly, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> reduces postprandial gallbladder contractility and delays gallbladder emptying, and up to 25 percent of patients develop asymptomatic cholesterol gallstones or sludge during the first 18 months of therapy [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H1108124125\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of glucocorticoids (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 60 mg) is reserved for patients with diarrhea who are refractory to somatostatin analogs [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H2535156\"><span class=\"h2\">Pancreatic resection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary tumors can be managed with distal pancreatomy. However, up to 60 percent have metastasized to lymph nodes, liver, kidneys, or bone at diagnosis [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/3,40\" class=\"abstract_t\">3,40</a>]. (See <a href=\"topic.htm?path=surgical-resection-of-lesions-of-the-body-and-tail-of-the-pancreas\" class=\"medical medical_review\">&quot;Surgical resection of lesions of the body and tail of the pancreas&quot;</a> and <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors#H185180803\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;, section on 'Others'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Management of advanced/metastatic disease</span></p><p class=\"headingAnchor\" id=\"H1664654976\"><span class=\"h3\">Liver-directed therapy for metastatic disease</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgery</strong> &ndash; Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, symptoms of hormone hypersecretion are effectively palliated, and prolonged survival is often possible given the slow-growing nature of these tumors.</p><p/><p class=\"bulletIndent1\">Postoperative complications include rebound gastric acid hypersecretion and intravascular fluid overload resulting from a shift of copious amounts of fluid from the intestinal lumen. Proton pump inhibitors and <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> are recommended in the preoperative and perioperative period to prevent these complications [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/30,31\" class=\"abstract_t\">30,31</a>]. Surgical resection for patients with metastases from pancreatic NET is discussed in detail, separately. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691406\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Surgical resection'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic artery embolization</strong> &ndash; Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Embolization can be performed via the infusion of gel foam powder into the hepatic artery through an angiography catheter (bland embolization) or in conjunction with chemotherapy (ie, <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, or <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a>, or drug-eluting beads) administered via the hepatic artery (chemoembolization). A third embolization technique uses radioactive isotopes (eg, yttrium-90 [90-Y]) that are tagged to glass or resin microspheres and delivered selectively to the tumor via the hepatic artery. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/41-56\" class=\"abstract_t\">41-56</a>]. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691449\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Hepatic artery embolization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Radiofrequency ablation and cryoablation </strong>&ndash; Ablation can be used as a primary treatment modality for neuroendocrine liver metastases or as an adjunct to surgical resection. Ablation can be performed percutaneously or laparoscopically and is less invasive than either hepatic resection or hepatic artery embolization. However, ablation is applicable only to smaller lesions (typically &lt;3 cm), and its long-term efficacy is uncertain [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H178294546\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Ablation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Liver transplantation</strong> &ndash; Liver transplantation is considered an investigational approach for metastatic pancreatic neuroendocrine tumors, including VIPoma, as the number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation has been attempted is small, and follow-up data are insufficient to judge whether complete cure has truly been achieved. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H178295652\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Liver transplantation'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1664650788\"><span class=\"h3\">Molecularly targeted therapy and other novel agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Molecularly targeted agents (eg, <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>) have a role in the management of patients with progressive advanced VIPomas. These and other novel therapies, such as peptide receptor radioligand therapy using radiolabeled somatostatin such as <a href=\"topic.htm?path=lutetium-lu-177-dotatate-drug-information\" class=\"drug drug_general\">lutetium Lu-177 dotatate</a>, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694077\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Molecularly targeted therapy'</a> and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694156\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Peptide receptor radioligand therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Cytotoxic chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who are highly symptomatic due to tumor bulk or who have rapidly enlarging metastases, chemotherapy has been used as initial treatment together with a somatostatin analog. The options for therapy include a streptozocin-based combination or a temozolomide-containing regimen [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/58-60\" class=\"abstract_t\">58-60</a>]. However, experience with systemic chemotherapy in patients with VIPomas is limited and few patients have been included in chemotherapy series. The use of cytotoxic chemotherapy in patients with pancreatic neuroendocrine tumors is discussed in detail elsewhere. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H199296649\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Cytotoxic chemotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">POST-TREATMENT SURVEILLANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is limited evidence from which to make recommendations for follow-up after resection of a VIPoma, and guidelines are based on expert consensus. Our approach for follow-up after treatment of a VIPoma is consistent with guidelines from the National Comprehensive Cancer Network and consists of the following [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/61\" class=\"abstract_t\">61</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Three to 12 months post-resection &ndash; History and physical examination, serum vasoactive intestinal polypeptide (VIP) level, and computed tomography or magnetic resonance imaging.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;One year post-resection to a maximum of 10 years &ndash; History and physical examination with serum VIP level every 6 to 12 months. Imaging studies as clinically indicated.</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The median survival of patients with VIPomas is 96 months [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"abstract_t\">62</a>]. Prognosis is largely dependent on VIPoma tumor grade, staging, and surgical resectability. Five- and ten-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors (both pancreatic neuroendocrine and carcinoid tumors) stratified by stage at presentation are presented in the table (<a href=\"image.htm?imageKey=ONC%2F80523\" class=\"graphic graphic_table graphicRef80523 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VIPomas are rare neuroendocrine tumors that secrete vasoactive intestinal polypeptide (VIP). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VIPomas are usually diagnosed between 30 and 50 years of age in adults and between two and four years of age in children. Pancreatic VIPomas are usually solitary, more than 3 cm in diameter, and occur in the tail of pancreas in 75 percent of patients. Approximately 60 to 80 percent of VIPomas have metastasized by the time of diagnosis. VIPomas usually occur as isolated tumors, but in 5 percent of patients they are part of the multiple endocrine neoplasia syndrome type 1 (MEN1).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VIPoma syndrome is characterized by watery diarrhea that persists even during fasting. The stools are tea-colored, odorless with stool volumes exceeding 700 <span class=\"nowrap\">mL/day</span>. In 70 percent of patients, stool volume can exceed 3000 <span class=\"nowrap\">mL/day</span>. Abdominal pain is mild or absent. Associated symptoms include flushing, lethargy, nausea, vomiting, muscle weakness, and muscle cramps. (See <a href=\"#H3\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with VIPoma have secretory diarrhea with a low osmotic gap (&lt;50 <span class=\"nowrap\">mOsm/kg)</span> (<a href=\"topic.htm?path=calculator-stool-osmolal-gap\" class=\"calc calc_professional\">calculator 1</a>). Hypochlorhydria occurs in 75 percent of patients. Other common laboratory findings include hyperglycemia and hypercalcemia. (See <a href=\"#H1081550664\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of a VIPoma is suspected in patients with unexplained high-volume secretory diarrhea. The diagnosis is established by a serum vasoactive intestinal polypeptide (VIP) concentration &gt;75 <span class=\"nowrap\">pg/mL</span>. However, a single elevated VIP level should be confirmed by repeat testing. (See <a href=\"#H390935\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-sectional imaging with multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen can localize the tumor and stage the extent of disease. If cross-sectional imaging is inconclusive, endoscopic ultrasound, somatostatin receptor scintigraphy, or <a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> <span class=\"nowrap\">PET/CT</span> should be performed to identify the tumor. In addition, we perform somatostatin receptor scintigraphy or 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> in patients with VIPomas if the finding of extra-abdominal metastases would change treatment. Because of its greater sensitivity, 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> is preferred over conventional somatostatin receptor scintigraphy, where available. (See <a href=\"#H391020\" class=\"local\">'Tumor localization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of a patient with a VIPoma begins with replacement of fluid losses and correction of electrolyte abnormalities. For treatment of the diarrhea, we suggest a somatostatin analog (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Treatment is initiated with short-acting <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (50 to 100 micrograms subcutaneously every eight hours) with rapid transition to a long-acting formulation and subsequent titration of dose to optimize symptom control. We reserve the use of glucocorticoids (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 60 mg) to patients with diarrhea that is refractory to somatostatin analogs. (See <a href=\"#H7\" class=\"local\">'Somatostatin analogs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary tumors arising in the tail of the pancreas can be managed with distal pancreatomy. However, up to 60 percent of VIPomas have metastasized to lymph nodes, liver, kidneys, or bone at diagnosis. (See <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;</a> and <a href=\"#H2535156\" class=\"local\">'Pancreatic resection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatic resection can be considered in patients with metastatic disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases. Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy may be used for palliation in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Long-term efficacy of radiofrequency ablation and cryoablation are unknown and experience with orthotopic liver transplantation is limited. Benefit has been shown for cytotoxic chemotherapy and molecularly targeted agents such as <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> and <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>. (See <a href=\"#H9\" class=\"local\">'Management of advanced/metastatic disease'</a> above and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The median survival of patients with VIPomas is 96 months. Our approach for follow-up after treatment of a VIPoma is consistent with guidelines from the National Comprehensive Cancer Network and consists of the following (see <a href=\"#H15\" class=\"local\">'Post-treatment surveillance'</a> above and <a href=\"#H16\" class=\"local\">'Prognosis'</a> above):</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Three to 12 months post-resection &ndash; History and physical examination, serum VIP level, and CT, or MRI.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;One year post-resection to a maximum of 10 years &ndash; History and physical examination with serum VIP level every 6 to 12 months. Imaging studies as clinically indicated.</p><p/><p class=\"headingAnchor\" id=\"H822858574\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Dr. Stephen E. Goldfinger, MD, for his past contributions as an author to this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"nounderline abstract_t\">Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987; 67:379.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"nounderline abstract_t\">Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995; 80:2273.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"nounderline abstract_t\">Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"nounderline abstract_t\">Lecorguill&eacute; M, Hammel P, Couvelard A, et al. [Jejunal vipoma]. Gastroenterol Clin Biol 2004; 28:797.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"nounderline abstract_t\">Meriney DK. Pathophysiology and management of VIPoma: a case study. Oncol Nurs Forum 1996; 23:941.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"nounderline abstract_t\">Bloom SR, Yiangou Y, Polak JM. Vasoactive intestinal peptide secreting tumors. Pathophysiological and clinical correlations. Ann N Y Acad Sci 1988; 527:518.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"nounderline abstract_t\">Krejs GJ. VIPoma syndrome. Am J Med 1987; 82:37.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"nounderline abstract_t\">Grier JF. WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 1995; 88:22.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"nounderline abstract_t\">Mekhjian HS, O'Dorisio TM. VIPoma syndrome. Semin Oncol 1987; 14:282.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"nounderline abstract_t\">Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332:725.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"nounderline abstract_t\">Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"nounderline abstract_t\">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"nounderline abstract_t\">Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"nounderline abstract_t\">Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170:1315.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"nounderline abstract_t\">Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"nounderline abstract_t\">Kirkwood KS, Debas HT. Neuroendocrine tumors: common presentations of uncommon diseases. Compr Ther 1995; 21:719.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"nounderline abstract_t\">King CM, Reznek RH, Dacie JE, Wass JA. Imaging islet cell tumours. Clin Radiol 1994; 49:295.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"nounderline abstract_t\">Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"nounderline abstract_t\">Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"nounderline abstract_t\">Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"nounderline abstract_t\">Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95:120.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"nounderline abstract_t\">Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"nounderline abstract_t\">&Ouml;berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii124.</a></li><li class=\"breakAll\">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524 (Accessed on June 08, 2016).</li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"nounderline abstract_t\">Rindi G, Kl&ouml;ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"nounderline abstract_t\">Cho JH, Ryu JK, Song SY, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016; 45:941.</a></li><li class=\"breakAll\">Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), AJCC, Chicago 2017. p.407.</li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"nounderline abstract_t\">Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"nounderline abstract_t\">O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989; 18:545.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"nounderline abstract_t\">Kraenzlin ME, Ch'ng JL, Wood SM, et al. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88:185.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"nounderline abstract_t\">Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"nounderline abstract_t\">Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"nounderline abstract_t\">Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/36\" class=\"nounderline abstract_t\">Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"nounderline abstract_t\">Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 2013; 40:56.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"nounderline abstract_t\">Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"nounderline abstract_t\">Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Cruz L, Blanco L, Cosa R, Rend&oacute;n H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32:904.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"nounderline abstract_t\">Sw&auml;rd C, Johanson V, Nieveen van Dijkum E, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96:517.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"nounderline abstract_t\">Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"nounderline abstract_t\">Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"nounderline abstract_t\">Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144:885.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"nounderline abstract_t\">Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175:408.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"nounderline abstract_t\">Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"nounderline abstract_t\">de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008; 19:855.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"nounderline abstract_t\">Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31:271.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"nounderline abstract_t\">Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247:1029.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"nounderline abstract_t\">King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"nounderline abstract_t\">Gaur SK, Friese JL, Sadow CA, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34:566.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"nounderline abstract_t\">Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol 2013; 20:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/53\" class=\"nounderline abstract_t\">Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/54\" class=\"nounderline abstract_t\">Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/55\" class=\"nounderline abstract_t\">Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83:887.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/56\" class=\"nounderline abstract_t\">Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/57\" class=\"nounderline abstract_t\">Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology 2006; 6:155.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/58\" class=\"nounderline abstract_t\">Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117:268.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/59\" class=\"nounderline abstract_t\">Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"nounderline abstract_t\">Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762.</a></li><li class=\"breakAll\">National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).</li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"nounderline abstract_t\">Roland CL, Bian A, Mansour JC, et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012; 105:595.</a></li><li><a href=\"https://www.uptodate.com/contents/vipoma-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"nounderline abstract_t\">Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2610 Version 25.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1081550639\" id=\"outline-link-H1081550639\">EPIDEMIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL FEATURES</a><ul><li><a href=\"#H1081550670\" id=\"outline-link-H1081550670\">Clinical manifestations</a></li><li><a href=\"#H1081550664\" id=\"outline-link-H1081550664\">Laboratory findings</a></li></ul></li><li><a href=\"#H390935\" id=\"outline-link-H390935\">DIAGNOSIS</a></li><li><a href=\"#H1081550940\" id=\"outline-link-H1081550940\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H391020\" id=\"outline-link-H391020\">TUMOR LOCALIZATION</a><ul><li><a href=\"#H1081551097\" id=\"outline-link-H1081551097\">Approach to imaging</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">STAGING</a></li><li><a href=\"#H1664653297\" id=\"outline-link-H1664653297\">TREATMENT</a><ul><li><a href=\"#H1081550698\" id=\"outline-link-H1081550698\">Symptomatic treatment</a><ul><li><a href=\"#H1081550705\" id=\"outline-link-H1081550705\">- Repletion of fluid and electrolytes</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Somatostatin analogs</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Glucocorticoids</a></li></ul></li><li><a href=\"#H2535156\" id=\"outline-link-H2535156\">Pancreatic resection</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Management of advanced/metastatic disease</a><ul><li><a href=\"#H1664654976\" id=\"outline-link-H1664654976\">- Liver-directed therapy for metastatic disease</a></li><li><a href=\"#H1664650788\" id=\"outline-link-H1664650788\">- Molecularly targeted therapy and other novel agents</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Cytotoxic chemotherapy</a></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">POST-TREATMENT SURVEILLANCE</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">PROGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H822858574\" id=\"outline-link-H822858574\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2610|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/59487\" class=\"graphic graphic_diagnosticimage\">- MRI pancreatic neuroendocrine tumor</a></li><li><a href=\"image.htm?imageKey=ONC/72303\" class=\"graphic graphic_diagnosticimage\">- MRI well differentiated pancreatic neuroendocrine tumor</a></li></ul></li><li><div id=\"GAST/2610|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/52546\" class=\"graphic graphic_table\">- Pathophysiology of clinical manifestations of the VIPoma syndrome</a></li><li><a href=\"image.htm?imageKey=GAST/65916\" class=\"graphic graphic_table\">- Major causes of chronic secretory diarrhea</a></li><li><a href=\"image.htm?imageKey=ONC/86409\" class=\"graphic graphic_table\">- ENETS staging system for pancreatic NETS</a></li><li><a href=\"image.htm?imageKey=ONC/111355\" class=\"graphic graphic_table\">- Neuroendocrine tumors of the pancreas TNM 2017</a></li><li><a href=\"image.htm?imageKey=ONC/80523\" class=\"graphic graphic_table\">- Survival rates following resection of a pancreatic NET</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-stool-osmolal-gap\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Stool osmolal gap</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings\" class=\"medical medical_review\">Approach to the adult with chronic diarrhea in resource-rich settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-hypokalemia-in-adults\" class=\"medical medical_review\">Clinical manifestations and treatment of hypokalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-hypercalcemia\" class=\"medical medical_review\">Diagnostic approach to hypercalcemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">Glucagonoma and the glucagonoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">Insulinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maintenance-and-replacement-fluid-therapy-in-adults\" class=\"medical medical_review\">Maintenance and replacement fluid therapy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-gastric-acid-secretion\" class=\"medical medical_review\">Physiology of gastric acid secretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=somatostatinoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Somatostatinoma: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-resection-of-lesions-of-the-body-and-tail-of-the-pancreas\" class=\"medical medical_review\">Surgical resection of lesions of the body and tail of the pancreas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">Surgical resection of sporadic pancreatic neuroendocrine tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Treatment of hypovolemia (dehydration) in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vasoactive-intestinal-polypeptide\" class=\"medical medical_review\">Vasoactive intestinal polypeptide</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}